BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

November 4, 2013 8:00 AM UTC

Amarin Corp. plc (NASDAQ:AMRN) fell $0.54 (25%) to $1.64 last week after disclosing that FDA said it no longer considers a change in serum triglyceride levels sufficient to "establish the effectiveness" of a compound for reducing cardiovascular risk in patients with triglyceride levels less than 500 mg/dL.

The agency revoked an SPA for Amarin's Phase III ANCHOR trial, which evaluated Vascepa icosapent ethyl in combination with statins to treat high triglycerides - defined as triglyceride levels 200 mg/dL or greater and less than 500 mg/dL - in patients with mixed dyslipidemia (see B11). ...